A phase III, open-label, randomized study of MPDL3280A (AntiPD-L1 antibody) in combination with carboplatin  Paclitaxel with or without bevacizumab compared with carboplatin  Paclitaxel  bevacizumab in chemotherapy naïve patients with stage IV non-squamous non-small cell lung cancer - Project - Authors - KSSG Research Database

Project

A phase III, open-label, randomized study of MPDL3280A (AntiPD-L1 antibody) in combination with carboplatin  Paclitaxel with or without bevacizumab compared with carboplatin  Paclitaxel  bevacizumab in chemotherapy naïve patients with stage IV non-squamous non-small cell lung cancer

Automatically Closed · 2016 until 2020

Früh Martin

Früh, Martin

Medizinische Onkologie und Hämatologie · Dept. I